Skip to main content

Research Repository

Advanced Search

Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: A prospective non-randomized study

Mwesigire, Doris Mutabazi; Wu, Albert W.; Martin, Faith; Katamba, Achilles; Seeley, Janet

Authors

Doris Mutabazi Mwesigire

Albert W. Wu

Faith Martin Faith.Martin@uwe.ac.uk
Wallscourt Fellow in Wellbeing and Mental Wealth

Achilles Katamba

Janet Seeley



Abstract

© 2015 Mwesigire et al. Background: The goal of antiretroviral therapy (ART) is to suppress viral replication, reduce morbidity and mortality, and improve quality of life (QoL). For resource-limited settings, the World Health Organization recommends a first-line regimen of two-nucleoside reverse-transcriptase inhibitors and one non-nucleoside transcriptase inhibitor (nevirapine (NVP) or efavirenz (EFV)). There are few data comparing the QoL impact of NVP versus EFV. This study assessed the change in QoL and factors associated with QoL among HIV patients receiving ART regimens based on EFV or NVP. Methods: We enrolled 640 people with HIV eligible for ART who received regimens including either NVP or EFV. QoL was assessed at baseline, three months and six months using Physical Health Summary (PHS) and Mental Health Summary (MHS) scores and the Global Person Generated Index (GPGI). Data were analyzed using generalized estimating equations, with ART regimen as the primary exposure, to identify associations between patient and disease factors and QoL. Results: QoL increased on ART. The mean QoL scores did not differ significantly for regimens based on NVP versus EFV during follow-up for MHS and GPGI regardless of CD4 stratum and for PHS among patients with a CD4 count >250 cells/μL. The PHS-adjusted β coefficients for ART regimens based on EFV versus NVP by CD4 count strata were as follows: -1.61 (95 % CI -2.74, -0.49) for CD4 count 250 cells/μL. The corresponding MHS-adjusted β coefficients were as follows: -0.39 (-1.40, 0.62) for CD4∈250 cells/μL. The GPGI-adjusted odds ratios for EFV versus NVP were 0.51 (0.25, 1.04) for CD4 count ∈250 cells/μL. QoL improved among patients on EFV over the 6-month follow-up period (MHS p∈

Citation

Mwesigire, D. M., Wu, A. W., Martin, F., Katamba, A., & Seeley, J. (2015). Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: A prospective non-randomized study. BMC Health Services Research, 15(1), https://doi.org/10.1186/s12913-015-0959-0

Journal Article Type Article
Acceptance Date Jul 14, 2015
Online Publication Date Jul 28, 2015
Publication Date Jul 28, 2015
Deposit Date Sep 18, 2019
Publicly Available Date Sep 18, 2019
Journal BMC Health Services Research
Electronic ISSN 1472-6963
Publisher BMC
Peer Reviewed Peer Reviewed
Volume 15
Issue 1
DOI https://doi.org/10.1186/s12913-015-0959-0
Keywords Health Policy
Public URL https://uwe-repository.worktribe.com/output/3069886

Files

Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study (497 Kb)
PDF

Licence
http://creativecommons.org/licenses/by/4.0/

Publisher Licence URL
http://creativecommons.org/licenses/by/4.0/

Copyright Statement
© 2015 Mwesigire et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited.



You might also like



Downloadable Citations